• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up

    7/7/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email

    SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or "Clover Health"), and a leading AI-powered physician enablement platform, today released findings within the whitepaper "Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in Post-Hospitalization Follow-up."

    The whitepaper examines the relationship between CA use by primary care physicians ("PCPs") and performance on high-risk care transition outcomes, including two HEDIS®1 quality measures within Clover Health’s Medicare Advantage population: Transitions of Care ("TRC") and Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions ("FMC").

    Counterpart Health partners with payers and provider organizations to help primary care teams identify care gaps, manage risk, and improve quality and financial performance across populations with complex clinical needs. For transitions of care, CA helps turn acute utilization events into timely, trackable follow-up work by generating tasks after hospital discharge and surfacing available hospitalization information, including medication information, lab results, procedures, and discharge summaries, within clinicians’ existing workflows.

    "Patients are at their most vulnerable when they are discharged from the hospital, where communication gaps and missed follow-ups with their PCP can lead to avoidable complications," said David Tsay, MD, PhD, Chief Medical Officer at Counterpart Health and co-author of the whitepaper. "CA is supporting PCPs in ensuring follow-up care happens, and that patients are getting the proactive and longitudinal care they need."

    Key highlights from the whitepaper include:

    • Stronger transitions of care performance: Members attributed to CA-enabled PCPs performed better across all HEDIS Transitions of Care measures reviewed, including notification of inpatient admission, patient engagement after discharge, receipt of discharge information, and medication reconciliation.
    • More frequent post-discharge coordination: Members attributed to CA-enabled PCPs had a 33% higher rate of receipt of discharge information and an 11% higher rate of medication reconciliation post-discharge.
    • More timely ED follow-up for high-risk members: Members attributed to CA-enabled PCPs had a 9% higher rate on the HEDIS FMC measure, which evaluates follow-up after emergency department visits for people with multiple high-risk chronic conditions.



    "Primary care providers are often best positioned to identify emerging risks and intervene before they escalate, but they need timely, actionable information to do so," said Conrad Wai, Chief Executive Officer of Counterpart Health. "This analysis highlights how Counterpart Assistant can help bridge the gap between hospital discharge and outpatient management. By equipping providers with insights that support timely follow-up and patient engagement, we believe CA can strengthen care coordination, reduce avoidable acute utilization, and contribute to lower total cost of care."

    This whitepaper is Counterpart’s eighth retrospective data analysis measuring CA's clinical impact, building on the care model and data foundation that supported Clover's #1 HEDIS score nationwide for a PPO Medicare Advantage plan for the last two years2. By embedding post-acute needs into the existing clinical workflow, CA helps enable more timely follow-up during one of the most vulnerable periods in a patient’s care journey.

    Counterpart Assistant is commercially available to interested plans and risk-bearing provider organizations looking to advance this work. To learn more about Counterpart Health, visit: www.counterparthealth.com.

    About Counterpart Health

    Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan. Counterpart Assistant is now commercially available, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies document the technology’s ability to support better outcomes in areas such as Diabetes, Chronic Kidney Disease, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease management, as well as Clinical Quality and Underserved Patient Populations.

    About Clover Health:

    Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale.

    Visit: www.cloverhealth.com

    Investor Relations:

    Ryan Schmidt

    investors@cloverhealth.com

    Press Inquiries:

    press@cloverhealth.com

    ______________________

    1 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

    2 This analysis focuses on performance by non-SNP PPO plans with over 2,000 lives as of September 1, 2025 and 2024 on HEDIS measures applicable to non-SNPs that were used for CMS’s MY 2023 and MY 2024 Star ratings, applying the measure ranges used by CMS.



    Primary Logo

    Get the next $CLOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Clover Health with a new price target

    Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

    12/17/24 8:33:41 AM ET
    $CLOV
    Medical Specialities
    Health Care

    UBS initiated coverage on Clover Health with a new price target

    UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

    10/7/24 7:45:42 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SVB Leerink reiterated coverage on Clover Health Investments with a new price target

    SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

    2/25/22 5:03:33 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Soares Karen sold $233,167 worth of shares (51,700 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,505,522 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    7/20/26 5:48:55 PM ET
    $CLOV
    Medical Specialities
    Health Care

    CEO, Medicare Advantage Reynoso Jamie L. sold $21,921 worth of shares (4,839 units at $4.53) as part of a pre-agreed trading plan, decreasing direct ownership by 0.17% to 2,814,640 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    7/17/26 5:26:40 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Chief Executive Officer Toy Andrew sold $292,860 worth of shares (62,711 units at $4.67), decreasing direct ownership by 0.65% to 9,547,114 units (SEC Form 4) (tax withholding)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    7/16/26 4:59:19 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026

    WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter. Second Quarter 2026 Conference Webcast Details: What: Clover Health’s Second Quarter 2026 Earnings Conference CallWhen: Wednesday, August 5, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-2q-2026-earning

    7/9/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up

    SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or "Clover Health"), and a leading AI-powered physician enablement platform, today released findings within the whitepaper "Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in Post-Hospitalization Follow-up." The whitepaper examines the relationship between CA use by primary care physicians ("PCPs") and performance on high-risk care transition outcomes, including two HEDIS®1 quality measures within Clover Health’s Medicare Advantage population: Transitions of Care ("

    7/7/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports First Quarter 2026 Results

    Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross ProfitMarket-leading Medicare Advantage membership growth with underlying trends tracking in line with expectationsExpect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-yearFirst quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-yearFirst q

    5/6/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/13/24 4:06:53 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    SEC Filings

    View All

    Clover Health Investments Corp. filed SEC Form 8-K: Other Events

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    7/17/26 4:05:10 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Other Events

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    6/18/26 4:05:28 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    6/16/26 4:05:44 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

    WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial

    9/18/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

    WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten

    7/29/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Financials

    Live finance-specific insights

    View All

    Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026

    WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter. Second Quarter 2026 Conference Webcast Details: What: Clover Health’s Second Quarter 2026 Earnings Conference CallWhen: Wednesday, August 5, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-2q-2026-earning

    7/9/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports First Quarter 2026 Results

    Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross ProfitMarket-leading Medicare Advantage membership growth with underlying trends tracking in line with expectationsExpect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-yearFirst quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-yearFirst q

    5/6/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/12/24 2:31:31 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/4/24 11:25:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    7/7/23 4:35:52 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care